DexCom (DXCM) vs Globus Medical (GMED)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
DexCom (DXCM) has outperformed Globus Medical (GMED) over the past year, gaining 24.5% versus a gain of 21.4%. Over five years, GMED leads with a -4.1% price change compared with -38.0% for DXCM. DexCom is the larger company by market cap ($31.62 billion vs $10.08 billion), about 3.1 times the size, while Globus Medical is growing revenue faster (+16.7% vs +15.6%).
On valuation, Globus Medical trades at a lower forward P/E (13.9x vs 26.8x for DexCom). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus 17.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | GMED |
|---|---|---|
| Share price | $83.79 | $75.11 |
| Market cap | $31.62B | $10.08B |
| 1-day change | -0.74% | +2.43% |
| YTD return | +27.18% | -16.01% |
| 1-year return | +24.54% | +21.37% |
| 5-year return | -37.99% | -4.06% |
| P/E ratio (TTM) | 33.25 | 19.26 |
| Forward P/E | 26.79 | 13.91 |
| EPS (TTM) | $2.52 | $3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $2.94B |
| Revenue growth (YoY) | +15.60% | +16.65% |
| Net income (latest FY) | $836.30M | $537.87M |
| Gross margin | 60.10% | 67.41% |
| Operating margin | 19.56% | 16.33% |
| Net margin | 17.94% | 18.30% |
| 52-week high | $92.59 | $101.40 |
| 52-week low | $54.11 | $56.50 |
| Distance from 52-week high | -9.51% | -25.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.85% | +34.36% |
| Average volume | 4.43M | 1.51M |
| Shares outstanding | 377.36M | 111.83M |
| Employees | 11,000 | 6,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 3.1 times larger than Globus Medical by market value ($31.62B vs $10.08B).
- DexCom trades at a higher earnings multiple (33.2x vs 19.3x trailing P/E).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
DXCM vs GMED FAQ
Which is bigger, DexCom or Globus Medical?
DexCom (DXCM) is larger, with a market capitalization of $31.62B compared with $10.08B for Globus Medical (GMED).
Which stock has performed better over the past year, DXCM or GMED?
DXCM returned +24.54% over the past 12 months, compared with +21.37% for GMED (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or GMED?
GMED has the lower trailing P/E at 19.3, versus 33.2 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DexCom and Globus Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.